Abstract
Bone marrow-derived antigen-presenting cells (APCs) play a central role in the induction of tolerance to tumor antigens expressed by B-cell lymphomas. Here we show that in vivo disruption of this APC-mediated tolerogenic mechanism unveils an intrinsic ability of malignant B cells to efficiently present tumor antigens to antigen-specific CD4 + T cells, resulting in a strong antitumor effect. This intrinsic antigen-presenting ability of malignant B cells is, however, overridden by tolerogenic bone marrow-derived APCs, leading instead to T-cell unresponsiveness and lack of antitumor effect. These results highlight the concept that therapeutic strategies aimed at enhancing the antigen-presenting function of B-cell lymphomas might not succeed unless the tolerogenic mechanisms mediated by bone marrow-derived APCs are disrupted in the first place.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2871-2878 |
| Number of pages | 8 |
| Journal | Blood |
| Volume | 107 |
| Issue number | 7 |
| DOIs | |
| State | Published - Apr 1 2006 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Biochemistry
- Immunology
- Hematology
- Cell Biology
Cite this
In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity. / Horna, Pedro; Cuenca, Alex; Cheng, Fengdong; Brayer, Jason; Wang, Hong Wei; Borrello, Ivan; Levitsky, Hyam; Sotomayor, Eduardo M.
In: Blood, Vol. 107, No. 7, 01.04.2006, p. 2871-2878.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity
AU - Horna, Pedro
AU - Cuenca, Alex
AU - Cheng, Fengdong
AU - Brayer, Jason
AU - Wang, Hong Wei
AU - Borrello, Ivan
AU - Levitsky, Hyam
AU - Sotomayor, Eduardo M.
PY - 2006/4/1
Y1 - 2006/4/1
N2 - Bone marrow-derived antigen-presenting cells (APCs) play a central role in the induction of tolerance to tumor antigens expressed by B-cell lymphomas. Here we show that in vivo disruption of this APC-mediated tolerogenic mechanism unveils an intrinsic ability of malignant B cells to efficiently present tumor antigens to antigen-specific CD4 + T cells, resulting in a strong antitumor effect. This intrinsic antigen-presenting ability of malignant B cells is, however, overridden by tolerogenic bone marrow-derived APCs, leading instead to T-cell unresponsiveness and lack of antitumor effect. These results highlight the concept that therapeutic strategies aimed at enhancing the antigen-presenting function of B-cell lymphomas might not succeed unless the tolerogenic mechanisms mediated by bone marrow-derived APCs are disrupted in the first place.
AB - Bone marrow-derived antigen-presenting cells (APCs) play a central role in the induction of tolerance to tumor antigens expressed by B-cell lymphomas. Here we show that in vivo disruption of this APC-mediated tolerogenic mechanism unveils an intrinsic ability of malignant B cells to efficiently present tumor antigens to antigen-specific CD4 + T cells, resulting in a strong antitumor effect. This intrinsic antigen-presenting ability of malignant B cells is, however, overridden by tolerogenic bone marrow-derived APCs, leading instead to T-cell unresponsiveness and lack of antitumor effect. These results highlight the concept that therapeutic strategies aimed at enhancing the antigen-presenting function of B-cell lymphomas might not succeed unless the tolerogenic mechanisms mediated by bone marrow-derived APCs are disrupted in the first place.
UR - http://www.scopus.com/inward/record.url?scp=33645500590&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33645500590&partnerID=8YFLogxK
U2 - 10.1182/blood-2005-07-3014
DO - 10.1182/blood-2005-07-3014
M3 - Article
C2 - 16339406
AN - SCOPUS:33645500590
VL - 107
SP - 2871
EP - 2878
JO - Blood
JF - Blood
SN - 0006-4971
IS - 7
ER -